ERBB2 and gastroesophageal junction adenocarcinoma: Recent results from the phase 3 DESTINY-Gastric04 trial (NCT04704934) demonstrated a statistically significant and clinically meaningful improvement in overall survival with T-DXd compared with ramucirumab and paclitaxel in patients with HER2+ unresectable and/or metastatic gastric or GEJ adenocarcinoma whose disease has progressed on or after a trastuzumab-containing regimen.24